



**2nd How to Diagnose and Treat
ACUTE LEUKAEMIA
March 13-15, 2020 - Budapest, Hungary
Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock**

Friday, March 13th, 2020

08:45-09:00 Welcome

SESSION I – Rare subsets of acute leukaemia

Chair: Gail Roboz (New York)

09:00-09:20 Case-based lecture : Charles Mullighan (Memphis)
Mixed phenotype acute leukaemias (B/M)

09:20-09:25 *Discussion*

09:25-09:45 Case-based lecture : Jonathan Bond (Dublin)
Interface acute leukaemias (T/M)

09:45-09:50 *Discussion*

09:50-10:10 Case-based lecture : Lucy Godley (Chicago)
Genetic predisposition to AML

10:10-10:15 *Discussion*

10:15-10:45 *Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)*

10:45-11:15 Coffee Break

SESSION II – Tracking leukaemic stem cells (LSCs)

Chair: Sylvie Freeman (Birmingham)

11:15-11:35 Case-based lecture : Andre Schuh (Toronto)
LSC signature

11:35-11:40 *Discussion*

11:40-12:00 Case-based lecture : Jacqueline Cloos (Amsterdam)
Flow identification and monitoring of LSC

12:00-12:05 *Discussion*

12:05-12:25 Case-based lecture : Emmanuelle Clappier (Paris)
MRD monitoring in Ph-positive ALL

12:25-12:30 *Discussion*

12:30-13:00 *Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)*

13:00-14:40 Lunch

13:30-14:30 Slot for a possible Symposium

SESSION III – Routine diagnosis gene expression and mutational profiling

Chair: Oliver Ottmann (Cardiff)

14:40-15:00 Case-based Lecture : Sabina Chiaretti (Rome)
Ph-like ALL diagnosis

15:00-15:05 *Discussion*

15:05-15:25 Case-based lecture : Josep-Maria Ribera (Barcelona)
Minimal / optimal gene panel in ALL ?

15:25-15:30 *Discussion*

15:30-15:50 Case-based lecture : Lars Bullinger (Berlin)
Minimal / optimal gene panel in AML ?

15:50-15:55 *Discussion*

15:55-16:25 *Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)*

16:25-16:55 Coffee break

16:55-17:35 DEBATE 1 – All patients with intermediate-risk AML must be transplanted

Chair: Andrew Wei (Melbourne)

16:55-17:10 Yes Charles Craddock (Birmingham)

17:10-17:15 *Discussion*

17:15-17:30 No Gail Roboz (New York)

17:30-17:35 *Discussion*

17:35-18:05 INTERACTIVE CASES 1 – Mutation-based therapy off-label

Chair: Jorge Sierra (Barcelona)

17:35-17:42 TKIs in Ph-like ALL Sarah Tasian (Philadelphia)

17:42-17:45 *Discussion*

17:45-17:52 GO for AML salvage therapy Nicolas Boissel (Paris)

17:52-17:55 *Discussion*

17:55-18:02 FLT3 inhibitors post-transplantation Andreas Burchert (Marburg)

18:02-18:05 *Discussion*

18:05-19:05 ROUNDTABLE 1 – Should we really use new targeted inhibitors as single agents ?

Chair: Christoph Röllig (Dresden)

18:05-18:25 Next-generation FLT3 inhibitors Alexander Perl (Philadelphia)

18:25-18:45 IDH1/2 inhibitors Courtney DiNardo (Houston)

18:45-18:55 *Discussion*

18:55 ***Get Together and Poster Walk (stand up cocktails and buffet dinner for all)***

Saturday, March 14th, 2020

08:00-9:00 **3 Simultaneous Meet the Expert sessions**

- | | |
|---|-----------------------------|
| 1. CNS prophylaxis and treatment in ALL | Wendy Stock (Chicago) |
| 2. MRD as a treatment-stratifying tool in AML | Sylvie Freeman (Birmingham) |
| 3. Acute leukaemia and pregnancy | Nicolas Boissel (Paris) |

SESSION IV – Addition of a 3rd agent to frontline 7+3

Chair : Andrew Wei (Melbourne)

09:10-09:30 Case-based lecture :
Midostaurin

Peter Paschka (Ulm)

09:30-09:35 *Discussion*

09:35-09:55 Case-based lecture :
Gemtuzumab ozogamicin

Juliette Lambert (Versailles)

09:55-10:00 *Discussion*

10:00-10:20 Case-based lecture :
Nucleoside analogs

Thomas Pabst (Bern)

10:20-10:25 *Discussion*

10:25-10:55 *Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)*

10:55-11:25 ***Coffee Break and Poster viewing***

11:25-12:05 **ROUNDTABLE 2 – Curative options for older AML**

Chair: Alexander Perl (Philadelphia)

11:25-11:40 Standard chemotherapy

Claude Gardin (Bobigny)

11:40-11:55 Liposomal daunorubicin/cytarabine

Jorge E. Cortes (Augusta)

11 :55-12 :10 Venetoclax/cytarabine-HMAs

Andrew Wei (Melbourne)

12:10-12:20 *Discussion*

12:20-12:40 **INTERACTIVE CASES 2**

Chair: Arnold Ganser (Hannover)

12:20-12:27 Management of high WBC APL

Pau Montesinos (Valencia)

12:27-12:30 *Discussion*

12:30-12:37 APL relapse after previous arsenic therapy

Lionel Ades (Paris)

12:37-12:40 *Discussion*

12:40-14:20 Lunch

13:10-14:10 Slot for a possible symposium

14:20-15:00 DEBATE 2 – Best treatment for NPM1-mutated AML in the next future ?

Chair: Hervé Dombret (Paris)

14:20-14:35 Intensive chemotherapy Christoph Röllig (Dresden)

14:35-14:40 *Discussion*

14:40-14:55 Targeted agents Ali Bazarbachi (Beyrouth)

14:55-15:00 *Discussion*

15:00-15:25 Coffee break and Poster Viewing

SESSION V- Allogeneic hematopoietic stem cell transplantation (HSCT)

Chair: Charles Craddock (Birmingham)

15:25-15:45 Case-based lecture : Jean-Hugues Dalle (Paris)
New GvHD prophylactic/curative treatment

15:45-15:50 *Discussion*

15:50-16:10 Case-based lecture : Jorge Sierra (Barcelona)
Haplo-identical HSCT

16:10-16:15 *Discussion*

16:15-16:35 Case-based lecture : Tiago Nava (Geneva)
Prevention and treatment of VOD

16:35-16:40 *Discussion*

16:35-17:05 *Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)*

17:20-18:20 Slot for a possible Symposium

Sunday, March 15th, 2020

08:00-09:00 3 Simultaneous Breakfast Meet the Expert Sessions

- | | |
|-------------------------------|--------------------------|
| 1. Therapy-related leukaemias | Arnold Ganser (Hannover) |
| 2. How I treat Ph+ ALL | Oliver Ottmann (Cardiff) |
| 3. How I treat older ALL | Hervé Dombret (Paris) |

08:30-09:30 Slot for a possible Symposium

SESSION VI – Immunotherapy for acute leukaemia

Chair: Wendy Stock (Chicago)

09:40-10:00 Case-based lecture : Max Topp (Würzburg)
Use of blinatumomab in ALL

10:00-10:05 *Discussion*

18/12/19

10:05-10:25 Case-based lecture : Françoise Méchinaud (Paris)
CAR T-cells for B-cell precursor ALL

10:25-10:30 *Discussion*

10:30-10:50 Case-based lecture : Navel Daver (Houston)
Immune check-point inhibitors in acute leukaemia

10:50-10:55 *Discussion*

10:55- 11:25 *Panel discussion (a 10-minute brief oral communication may be integrated before the panel discussion)*

11:25-11:55 *Coffee break*

11:55-12:35 DEBATE 3 – T-ALL: where are we going now?
Chair: Nicolas Boissel (Paris)

11:55-12:10 Standard and new options for T-ALL David Teachy (Philadelphia)

12:10-12:15 *Discussion*

12:15-12:30 CAR T-cells for T-ALL John DiPersio (Saint-Louis)

12:30-12:35 *Discussion*

12:35-12:45 *Closing remarks*

MEETING CLOSURE